Tris, di-( organotitanium) substituted tungstosilicates α,β - (CpTi)3(SiW9037)17– and γ-[(CpTi)2(SiW10O38)] 6– were prepared by the reaction of C2TiC12 (Cp= η-C5H5) with a,β-SiW9 O9/34(noted α,β Siv9,), γ-Si...Tris, di-( organotitanium) substituted tungstosilicates α,β - (CpTi)3(SiW9037)17– and γ-[(CpTi)2(SiW10O38)] 6– were prepared by the reaction of C2TiC12 (Cp= η-C5H5) with a,β-SiW9 O9/34(noted α,β Siv9,), γ-SiWO8/36 (noted γ-SiW10) The products were characterized by means of elemental analysis, IR, 1H NMR, 183W NMR and polarography. 183W NMR spectra of the complexes support the stoichiometry of the new heteropolyanions and the probable retention of the A-XW9 or γ-SiWlO units. And the organotitanium substituted compounds showed promising in vitro antitumor activity in two of human tumor cell lines.展开更多
文摘Tris, di-( organotitanium) substituted tungstosilicates α,β - (CpTi)3(SiW9037)17– and γ-[(CpTi)2(SiW10O38)] 6– were prepared by the reaction of C2TiC12 (Cp= η-C5H5) with a,β-SiW9 O9/34(noted α,β Siv9,), γ-SiWO8/36 (noted γ-SiW10) The products were characterized by means of elemental analysis, IR, 1H NMR, 183W NMR and polarography. 183W NMR spectra of the complexes support the stoichiometry of the new heteropolyanions and the probable retention of the A-XW9 or γ-SiWlO units. And the organotitanium substituted compounds showed promising in vitro antitumor activity in two of human tumor cell lines.
